Advice

following a resubmission

alogliptin (Vipidia®) is accepted for restricted use within NHS Scotland.

Indication under review: For adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.

SMC restriction: dual therapy

  • In combination with metformin, when metformin alone, together with diet and exercise does not provide adequate glycaemic control in patients for whom the addition of a sulfonylurea is inappropriate.
  • In combination with a sulfonylurea, when sulfonylurea alone, together with diet and exercise does not provide adequate glycaemic control in patients for whom the addition of metformin is inappropriate due to contra-indications or intolerance.

Treatment with alogliptin reduces glycosylated haemoglobin, HbA1c, significantly more than placebo when used in combination with metformin or sulfonylurea.

SMC cannot recommend the use of alogliptin as single therapy or triple therapy as the company’s submission related only to its use in dual therapy.

Download detailed advice183KB (PDF)

Download

Medicine details

Medicine name:
alogliptin (Vipidia)
SMC ID:
937/14
Indication:
For adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.
Pharmaceutical company
Takeda UK Ltd
BNF chapter
Endocrine system
Submission type
Resubmission
Status
Restricted
Date advice published:
13 October 2014